NCT01837719View on ClinicalTrials.gov

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
DRUG

Atazanavir

300-mg capsule

DRUG

Cobicistat

150-mg tablet

DRUG

Atazanavir/Cobicistat FDC

Atazanavir 300-mg/cobicistat 150-mg FDC tablet

Trial Locations (1)

78744

Ppd Development, Inc., Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01837719 - Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat | Biotech Hunter | Biotech Hunter